Stocktoria
Vaxart, Inc. VXRT
OTC · OOTC · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1980-03-17
Vaxart, Inc. financials (annual, from 10-K)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $237.3M | $28.7M | $7.4M | $107,000 | $892,000 | $4.0M | $9.9M | $4.2M | $5.8M | $8.9M |
| R&D expense | $201.6M | $74.2M | $68.1M | $81.1M | $48.7M | $19.9M | $14.5M | $17.3M | $12.4M | $28.3M |
| Operating income | $18.1M | -$66.3M | -$83.3M | -$114.6M | -$72.8M | -$30.2M | -$15.8M | -$21.8M | -$10.0M | -$27.5M |
| Interest expense | — | — | — | — | $0 | $0 | $315,000 | $821,000 | $3.0M | — |
| Income tax | $476,000 | $260,000 | $261,000 | $67,000 | $107,000 | $238,000 | $490,000 | $109,000 | — | $300,000 |
| Net income | $16.3M | -$66.9M | -$82.5M | -$107.8M | -$70.5M | -$32.2M | -$18.6M | -$18.0M | -$9.6M | -$29.4M |
| EPS (diluted) | $0.07 | $-0.33 | — | — | — | — | — | — | — | $-0.76 |
| Operating cash flow | $7.7M | -$44.8M | -$70.5M | -$94.8M | -$59.8M | -$23.8M | -$13.1M | -$14.5M | -$10.0M | -$30.0M |
| Free cash flow | $7.6M | -$45.3M | -$72.3M | -$104.4M | -$65.0M | -$25.0M | -$13.9M | -$15.3M | -$10.2M | — |
| Cash & equivalents | — | — | $34.8M | $44.0M | $143.7M | — | — | $11.5M | $1.6M | $2.6M |
| Total assets | $186.1M | $166.4M | $91.8M | $153.8M | $221.2M | $152.6M | $37.0M | $35.2M | $4.5M | $40.1M |
| Total liabilities | $98.3M | $107.5M | $34.0M | $43.2M | $33.6M | $29.2M | $24.1M | $24.0M | $43.2M | $21.4M |
| Shareholders' equity | $87.8M | $58.9M | $57.8M | $110.6M | $187.5M | $123.4M | $13.0M | $11.2M | -$38.7M | $18.7M |
Growth · year-over-year · Revenue CAGR 44%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +726.7% | +288.9% | +6796.3% | -88.0% | -78.0% | -59.0% | +137.1% | -28.8% | -34.4% | -4.3% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0000072444 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.